Capitalmind
Capitalmind
Premium

Strides Up 12% on FDA Approval, Portfolio Gains

This is a Capital Mind Premium post, sent on April 26, 2014. Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor ...